Claims
- 1. A compound of structural Formula I or its pharmaceutically acceptable salts: ##STR4## R.sub.1 is independently H or a C.sub.1 -C.sub.8 alkyl; R.sub.2 is H, C.sub.1 -C.sub.3 alkyl, a halogen, OCH.sub.3, OCF.sub.3, CF.sub.3, CN, SCH.sub.3 or NHCOCH.sub.3 ; and
- R.sub.3 is H, C.sub.1 -C.sub.3 alkyl, a halogen, OCH.sub.3, OCF.sub.3, CF.sub.3, CN, SCH.sub.3 or NHCOCH.sub.3 with the proviso at least one R.sup.1 is C1-C8 alkyl; with the further proviso that when r.sup.2 and r.sup.3 are both hydrogen then the R.sup.1 's are both C1-C8 alkyl; and with the further proviso that when one of R.sup.2 and r.sup.3 is p-methoxy, and the other is hydrogen, then the R.sup.1 's cannot both be ethyl.
- 2. The compound of claim 1 wherein said R.sub.1 's are independently H or C.sub.1-6 alkyl.
- 3. The compound of claim 2 wherein one of said R.sub.1 is propyl.
- 4. The compound of claim 1 wherein said R.sub.2 and R.sub.3 are both Cl.
- 5. The compound of claim 1 wherein said R.sub.2 is hydrogen and said R.sub.3 is Cl.
- 6. The compound of claim 1 wherein said R.sub.2 is hydrogen and said R.sub.3 is --OCF.sub.3.
- 7. The compound of claim 1 which is:
- a) 2-[4-(4-chlorobenzenesulfonamido)phenyl]ethyl-1-dipropylamine;
- b) 2-[4-(4-acetamidobenzenesulfonamido)phenyl]ethyl-1-dipropylamine;
- c) 2-[4-(2,4-dichlorobenzenesulfonamido)phenyl]ethyl-1-propylamine;
- d) 2-[4-(4-chlorobenzenesulfonamido)phenyl]ethyl-1-propylamine;
- e) 2-[4-(4-trifluoromethoxybenzenesulfonamido)phenyl]ethyl-1-propylamine;
- f) 2-[4-(2-chloro-4-fluorobenzenesulfonamido)phenyl]ethyl-1-propylamine;
- g) 2-[4-(4-bromobenzenesulfonamido)phenyl]ethyl-1-propylamine;
- h) 2-[4-[(4-trifluoromethyl)benzenesulfonamido]phenyl]ethyl-1-propylamine;
- i) 2-[3-(2-fluorobenzenesulfonamido)phenyl]ethyl-1-propylamine; or
- j) 2-[3-(3-chlorobenzenesulfonamido)phenyl]ethyl-1-propylamine.
- 8. The compound of claim 1, wherein said R.sup.2 is hydrogen and said R.sup.3 is -CF.sub.3.
- 9. A method for treating central nervous system disorders associated with dopamine D3 receptor activity comprising:
- administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I of claim 1.
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Ser. No. 60/085,493, filed May 14, 1998, under 35 USC 119(e)(i).
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3574741 |
Gould |
Apr 1971 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0 611 003 A1 |
Aug 1994 |
EPX |